Myeloproliferative disorders
Shirakawa, S.
Nihon Rinsho. Japanese Journal of Clinical Medicine 35(Suppl 1): 994-995
1977
ISSN/ISBN: 0047-1852 PMID: 613085 Document Number: 120357
Document emailed within 1 workday
Related Documents
Saumur, J.H.; Coleman, M.L.; Larson, L.M. 1979: Hematology problem. Myeloproliferative disorders American Journal of Medical Technology 45(7): 634-637Tefferi, A. 1999: Introduction: overview of chronic myeloproliferative disorders Seminars in Hematology 36(1 Suppl. 2): 1-2
Bhattacharya, D.K. 1975: Kinetics of the blood platelets in myeloproliferative disorders Indian Journal of Cancer 12(2): 192-198
Landolfi, R.; Marchioli, R.; Patrono, C. 1997: Mechanisms of bleeding and thrombosis in myeloproliferative disorders Thrombosis and Haemostasis 78(1): 617-621
Iseki, T. 1993: Vitamin B12 and transcobalamin in chronic myeloproliferative disorders Rinsho Byori. Japanese Journal of Clinical Pathology 41(12): 1310-1321
Tefferi, A. 2007: The recent advances in classic BCR-ABL-negative myeloproliferative disorders Clinical Advances in Hematology and Oncology: H&o 5(2): 113-115
Muratore, R.; Follana, R.; Khayati, A.; Olmer, J. 1973: Morphological abnormalities of polymorphonuclear neutrophils during myeloproliferative disorders Nouvelle Revue Francaise d'Hematologie 13(3): 376-380
Taylor, K.M.; Shetta, M.; Talpaz, M.; Kantarjian, H.M.; Hardikar, S.; Chinault, A.C.; McCredie, K.B.; Spitzer, G. 1989: Myeloproliferative disorders: usefulness of X-linked probes in diagnosis Leukemia 3(6): 419-422
Ruggeri, M.; Castaman, G.; Rodeghiero, F. 1993: Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders? Haematologica 78(6 Suppl 2: 18-21
Cortelazzo, S.; Barbui, T.; Bassan, R.; Dini, E. 1980: Abnormal aggregation and increased size of platelets in myeloproliferative disorders Thrombosis and Haemostasis 43(2): 127-130
Bonaccorso, R.; Teresi, M.; Gebbia, V.; Tambone Reyes, M.; Tinnirello, D.; Di Marco, P.; Citarrella, P.; Mansueto, S. 1989: Recombinant alpha 2 interferon in the treatment of chronic myeloproliferative disorders Journal of ChemoTherapy 1(4 Suppl): 1266-1268
Russell, N.H.; Salmon, J.; Keenan, J.P.; Bellingham, A.J. 1981: Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders Thrombosis Research 22(4): 389-397
Romano, J.; Safai, B. 1979: Pyoderma gangrenosum and myeloproliferative disorders. Report of a case and review of the literature Archives of Internal Medicine 139(8): 932-934
Han, Z.C.; Briere, J.; Parent, D.; Abgrall, J.F.; Sensebe, L. 1988: Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders Journal of Biological Regulators and Homeostatic Agents 2(3): 119-124
Ward, H.P.; Vautrin, R.; Swasdikul, D. 1971: Effect of serum from myeloproliferative disorders on erythropoietin-sensitive stem cells Journal of Laboratory and Clinical Medicine 78(5): 849
Kreipe, H.; Radzun, H.J.; Bartels, H.; von Heyden, H.W.; Löffler, H.; Parwaresch, M.R. 1990: Clonality and stem cell defects in the molecular pathology of chronic myeloproliferative disorders Verhandlungen der Deutschen Gesellschaft für Pathologie 74: 49-64
Fritsch, R.S.; Maschek, H.; Ehlerding, C.; Widjaja, W.; Choritz, H.; Georgii, A. 1990: Granulopoiesis in chronic myeloproliferative disorders (CMPD): electron microscopy/morphometric investigations Verhandlungen der Deutschen Gesellschaft für Pathologie 74: 216-219
Kemnitz, J.; Freund, M.; Diminis, M.; Cohnert, T.; Uysal, A.; Georgii, A. 1990: Detection of cells with phenotype of multiple drug resistance in myeloproliferative disorders before the treatment Gematologiia i Transfuziologiia 35(2): 15-18
Dulícek, P.; Voglová, J.; Malý, J. 2010: Surgical interventions in patients with myeloproliferative disease--prophylaxis and treatment of haemostatic disorders Vnitrni Lekarstvi 56(1): 61-66
Sréter, L.; Kárteszi, M.; Fehér, J.; Lutz, D. 1988: Serum type-III-procollagen and laminin concentration after interferon therapy in chronic myeloproliferative disorders Acta Medica Hungarica 45(3-4): 323-328